Home
About Our Team
Our Pipeline
News
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
Filings
Annual Reports
Quarterly Results
Stock Information
Historic Stock Lookup
Analyst Coverage
FAQs
Contact Us
News
Therapeutics’ Largest Institutional Shareholder Converts Existing Series Preferred Stock Into Common Stock Streamlining Its Capital Structure
January 15, 2019 | Press Release
Announces Extension of $10 Million Line Credit
December 20, 2018 | Press Release
View the presentation from the 2nd Annual Anti-Fibrotic Drug Development Summit
November 29, 2018 | Presentation
Read more
Corporate Update
An updated overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.
Presentation
detailed review of the company's late-breaker presentation at The International Liver Congress, which reinforces and extends the positive effects of GR-MD-02 in patients with cirrhosis.
Summit
detailed review of the company's keynote presentation at The 2nd Annual Nash Summit, providing in-depth insight on clinical trials and endpoints in cirrhosis and an overview of the NASH-Clinical Trial.
Supplemental presentation on GR-MD-02 for Combination Cancer Immunotherapy
detailed review of the use of GR-MD-02 in combination therapy with in advanced melanoma.
Therapeutics, Inc.
NASDAQ: GALT
Filings & Reports
Corporate Snapshot
Latest Corporate Presentation
Media Fact Sheet
Subscribe
Compassionate Use Policy
|
Privacy Policy
|
Terms of Use
|
Site Map
 Disclaimer: This site may contain 
forward-looking informationis pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies.
© 2019 Inc. - All Rights ReservedHarold Shlevin, Ph.D.
President and chief executive officer
Dr. Shlevin is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics and vaccines.  Before joining Therapeutics, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals; co-founder of Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, president and chief executive officer of Tikvah Therapeutics, a company focused on clinical development of for treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics.  Dr. Shlevin earned his from Boston University and and Ph.in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as assistant professor of pharmacology and physiology. He is a member of scientific and business societies including the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents.
Jack Callicutt, CPA
Chief financial officer
Mr. Callicutt has over 24 years of public and private company experience including more than a decade of audit, tax and registrant experience with a major accounting firm. He was most recently chief financial officer for Health, Inc., a telemedicine firm, where he completed a $4 million private placement. Previous positions include chief financial officer of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include chief financial officer roles at private companies including and Tikvah Therapeutics, and at Coratus Genetics, a publicly-traded biopharmaceutical company. Mr. Callicutt is a certified public accountant and graduated cum laude with a degree in accounting and computer science from Delta State University.
Rex Horton
Executive director of regulatory affairs and quality assurance
Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory affairs matters including drugs, biologics and vaccines. He has broad range of regulatory affairs and quality leadership experience that is directly relevant to Therapeutics’ development programs, with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas, including gastroenterology. He was most recently was director of regulatory affairs at Chelsea Therapeutics, where he successfully led the organization through its first filing and favorable Advisory Committee Meeting. In past leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel® Stickpack, Creon® Capsules and Luvox® Capsules. He has also provided chemistry, manufacturing and controls (CMC) regulatory leadership and support of INDs and NDAs, including Estrogel® and Androgel® Pump. Mr. Horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by Solvay in its interactions with the He earned his Bachelor’s degree in industrial/manufacturing and systems engineering from the Georgia Institute of Technology. He is a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and American Association of Pharmaceutical Scientists (AAPS).
Adam Allgood, Pharm.D., R.Ph.
Executive director of clinical development
Dr. Allgood is an experienced industry professional with more than 28 years of pharmaceutical industry experience in effectively designing, implementing, monitoring, and directing clinical programs in all four phases of clinical development, ranging from Phase 1 first-in-human trials to large global Phase 3 clinical trials and post marketing trials. His therapeutic expertise spans a variety of therapeutic areas including gastroenterology, and encompasses clinical trial leadership, key opinion leader interface, significant contract research organization management experience, clinical trial investigator training, and clinical advisory board responsibilities. In addition, Dr. Allgood has extensive clinical research and/or regulatory experience in immunology, rheumatology, neurology, and women’s health. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at Inc., a multinational biopharmaceutical company. His prior positions include leadership roles at Abbott Laboratories and Solvay Pharmaceuticals in regulatory affairs, clinical development and medical affairs. Dr. Allgood earned his Doctor of Pharmacy (Pharm.D.) degree summa cum laude from Mercer University College of Pharmacy and Health Sciences in Atlanta and is a Registered Pharmacist (R.Ph.). He is a member of the American Pharmacists Association (APHA), the Georgia Pharmacy Association (GPHA), and the Association of the United States Army (AUSA).
Eliezer Zomer, Ph.D.
Vice President, discovery research and product development
Dr. Zomer is the founder of Alicon Biological Control, where he served from 2000 to 2002. He was vice president of product development at SafeScience, Inc., from 1998 to 2000, and from 1987 to 1998 was vice president of research and development at Charm Sciences, Inc. Dr. Zomer received a B.Sc. degree in industrial microbiology from the University of Tel Aviv, a Ph.in biochemistry from the University of Massachusetts in 1978, and completed his post-doctoral study at the National Institutes of Health.
© 2019 Inc. - All Rights ReservedChief Executive Officer and President
Dr. Shlevin is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics and vaccines. Before joining Therapeutics, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US; co-founder of Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, president and chief executive officer of Tikvah Therapeutics, a company focused on clinical development of for treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics. Dr. Shlevin earned his from Boston University and and Ph.in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as assistant professor of pharmacology and physiology. He is a member of scientific and business societies including the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents. Dr. Shlevin currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ:CRME) and as an advisor to Clearside Biomedical, Inc.
Jack                   Callicutt,          CPA
Chief financial officer
Mr. Callicutt has over 24 years of public and private company experience including more than a decade of audit, tax and registrant experience with a major accounting firm. He was most recently chief financial officer for Health, Inc., a telemedicine firm, where he completed a $4 million private placement. Previous positions include chief financial officer of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include chief financial officer roles at private companies including and Tikvah Therapeutics, and at Coratus Genetics, a publicly-traded biopharmaceutical company. Mr. Callicutt is a certified public accountant and graduated cum laude with a degree in accounting and computer science from Delta State University.
Rex                 Horton
Executive director of regulatory affairs and quality assurance
Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory affairs matters including drugs, biologics and vaccines. He has broad range of regulatory affairs and quality leadership experience that is directly relevant to Therapeutics’ development programs, with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas, including gastroenterology. He was most recently was director of regulatory affairs at Chelsea Therapeutics, where he successfully led the organization through its first filing and favorable Advisory Committee Meeting. In past leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel® Stickpack, Creon® Capsules and Luvox® Capsules. He has also provided chemistry, manufacturing and controls (CMC) regulatory leadership and support of INDs and NDAs, including Estrogel® and Androgel® Pump. Mr. Horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by Solvay in its interactions with the He earned his Bachelor’s degree in industrial/manufacturing and systems engineering from the Georgia Institute of Technology. He is a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and American Association of Pharmaceutical Scientists (AAPS).
Adam                   Allgood,          Pharm.D., R.Ph.
Executive director of clinical development
Dr. Allgood is an experienced industry professional with more than 28 years of pharmaceutical industry experience in effectively designing, implementing, monitoring, and directing clinical programs in all four phases of clinical development, ranging from Phase 1 first-in-human trials to large global Phase 3 clinical trials and post marketing trials. His therapeutic expertise spans a variety of therapeutic areas including gastroenterology, and encompasses clinical trial leadership, key opinion leader interface, significant contract research organization management experience, clinical trial investigator training, and clinical advisory board responsibilities. In addition, Dr. Allgood has extensive clinical research and/or regulatory experience in immunology, rheumatology, neurology, and women’s health. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at Inc., a multinational biopharmaceutical company. His prior positions include leadership roles at Abbott Laboratories and Solvay Pharmaceuticals in regulatory affairs, clinical development and medical affairs. Dr. Allgood earned his Doctor of Pharmacy (Pharm.D.) degree summa cum laude from Mercer University College of Pharmacy and Health Sciences in Atlanta and is a Registered Pharmacist (R.Ph.). He is a member of the American Pharmacists Association (APHA), the Georgia Pharmacy Association (GPHA), and the Association of the United States Army (AUSA).
Eliezer                 Zomer,          Ph.D.
Vice President, discovery research and product development
Dr. Zomer is the founder of Alicon Biological Control, where he served from 2000 to 2002. He was vice president of product development at SafeScience, Inc., from 1998 to 2000, and from 1987 to 1998 was vice president of research and development at Charm Sciences, Inc. Dr. Zomer received a B.Sc. degree in industrial microbiology from the University of Tel Aviv, a Ph.in biochemistry from the University of Massachusetts in 1978, and completed his post-doctoral study at the National Institutes of Health.Contact Us
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
Filings
Annual Reports
Quarterly Reports
Stock Information
Historic Stock Lookup
Analyst Coverage
FAQs
Newsroom
Home
Who We Are
What We Do
Who We Help
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
Stock Information
FAQs
Email Alert Subscription
Home
Investor Relations
GOVERNANCE
The Board of Directors of Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Committee Charters
Title
View
Add Files
Nominating and Corporate Governance Committee
 744.5 KB
Add Files
Nominating and Corporate Governance Committee
 744.5 KB
Add Files
Audit Committee
 762.3 KB
Add Files
Audit Committee
 762.3 KB
Add Files
Compensation Committee
 756.4 KB
Add Files
Compensation Committee
 756.4 KB
 Governance Documents
Title
View
Add Files
Code of Conduct and Ethics
 51.2 KB
Add Files
Code of Conduct and Ethics
 51.2 KB
Shareholder Tools
Download Library
Compassionate Use Policy
|
Privacy Policy
|
Terms of Use
|
Site Map
forward-looking information
.
var s_CCSWebHostingAccount = "trcgclientweb1268";Chairman of the board from May 2018, Director since December 2017
Richard Uihlein, co-founded Uline, Inc. (a leading distributor of shipping, packaging and industrial supplies) in 1980, and has served as its Chief Executive Officer and Chairman since its’ founding. Prior to founding Uline Inc., Mr. Uihlein was employed at General Bindings Corp., Northbrook, from 1967 to 1980. Mr. Uihlein graduated from Stanford University, Palo Alto, California with a degree in history in 1967.
Chairman of the Board
Marc                 Rubin,          M.D.
Director since October 2011, Chairman of the board from January 2016 to May 2018, Lead Director from May 2015 to January 2016
Dr. Rubin is Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering in June 2006, Dr. Rubin was a member of the Executive Board of Schering since joining the company in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company.
Independent Director
Gilbert                   Amelio,           Ph.D.
Director since February 2009
Mr. Amelio began his career at Bell Labs in Murray Hill, New Jersey. Since January 1, 2012, Dr. Amelio has provided consulting and advisory services through GFA, LLC, a California limited liability company. He was a Senior Partner of Sienna Ventures (a privately-held venture capital firm in Sausalito, California) from April 2001 until the fund closed per plan on December 31, 2011. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (now a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, (a full-service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft Ventures, (a consulting firm in Newport Beach, California) from April 1997 to December 2004. Dr. Amelio was elected a Director of AT&in February 2001 and had previously served as an Advisory Director of AT&(then known as Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&in 1997. Prior to 1997, he served as Chairman, President and of National Semiconductor (1991-1996) and Apple Computer (1996-1997).
Kevin                   Freeman,          CFA
Vice Chairman of the board form May 2018, Director since May 2011
Mr. Freeman holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times bestselling book about the stock market and economy. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a in business administration from University of Tulsa, Tulsa, Oklahoma.
Director since December 2017
Mr. Lewis is the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he has held since 2007. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. Mr. Lewis received his undergraduate degree from the University of Illinois at Urbana-Champaign and his Masters in Science of Taxation from DePaul University.
Director since December 2017
Mr. Shulman is the Chief Executive Officer of Medical Devices Inc. (MDI), a position he has held since 1982. is responsible for numerous medical device startups such as defibrillator electrodes, Fiberoptic pressure sensors, occlusive dressings, surgical glue, non-invasive body temperature control and end stage renal care. Prior to the formation of MDI, he was Director of Sales and Marketing/Asia Pacific for Medtronic from 1970 to 1981. Mr. Shulman received a in microbiology and physics from Wayne State University.
Director since September 2014
Dr. Omenn is a director of Amgen, Inc., and Armune Biosciences, Inc. He is a professor of internal medicine, human genetics and public health, and director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He leads major research programs in proteomics and integrative biomedical informatics. Dr. Omenn served as executive vice president for medical affairs and as chief executive officer of the University of Michigan Health System from 1997 to 2002. Earlier, he was the dean of the School of Public Health and Community Medicine and professor of medicine at the University of Washington. Dr. Omenn is the author of more than 460 research papers and scientific reviews and author/editor of 18 books. He received the John Gardner Legacy of Leadership Award from the White House Fellows Association in 2004 and the Walsh McDermott Award from the Institute of Medicine in 2008. He is vice president of the International Human Proteome Organization. Dr. Omenn received his summa cum laude from Princeton University, magna cum laude from Harvard Medical School, and Ph.in genetics from the University of Washington.
Director since 2018
Kary Eldred is a director and Chief Investment Officer for the Living Stones Foundation since July 2015 and has been an active private equity investor for many years. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of Semiconductor. From January 2011 through October 2014, Mr. Eldred was & Chairman of Altadona, a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become publicly listed on different exchanges around the world including the NASDAQ, and the market. Mr. Eldred has an Executive from Business School and a in Foreign Service from Baylor University.
Director since February 2009, Executive Chairman from February 2010 to January 2016, Co-Founder in 2000
Mr. Czirr is a co-founder of 10Fund, and is a managing member of 10Capital Management LLC, the general partner of 10Fund, Mr. Czirr was a co-founder of in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anticancer drugs, served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the cause of solid tumors, and was a consultant to Metalline Mining Company Inc., now known as Silver Bull Resources, Inc., (AMEX: SVBL), a mineral exploration company seeking to become a low cost producer of zinc. Mr. Czirr received a degree from the University of Michigan.Contact Us
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
Filings
Annual Reports
Quarterly Reports
Stock Information
Historic Stock Lookup
Analyst Coverage
FAQs
Newsroom
Home
Who We Are
What We Do
Who We Help
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
Stock Information
FAQs
Email Alert Subscription
Home
Investor Relations
GOVERNANCE
Committee Composition
Independent Director
Audit Committee
Compensation Committee
Nominating and Governance Committee
IR/Committee
 Marc  Rubin, M.D.
Independent Director
Nominating and Governance Committee
 Gilbert Amelio,  Ph.D.
Compensation Committee
Nominating and Governance Committee
 Kevin Freeman, CFA
Audit Committee
Nominating and Governance Committee
 Joel   Lewis  
Audit Committee
Compensation Committee
 Stephen   Shulman 
IR/Committee
 Gilbert Omenn, M.D., Ph.D
Compensation Committee
 Kary  Eldred 
Audit Committee
 James Czirr 
IR/Committee
= Independent Director
= Chairperson
= Member
Shareholder Tools
Download Library
Compassionate Use Policy
|
Privacy Policy
|
Terms of Use
|
Site Map
forward-looking information
.
var s_CCSWebHostingAccount = "trcgclientweb1268";